Last updated on August 2019

Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) Versus Lenvatinib as First-line Therapy in Participants With Advanced Hepatocellular Carcinoma (MK-7902-002/E7080-G000-311/LEAP-002)


Brief description of study

The purpose of this study is to evaluate the safety and efficacy of lenvatinib (E7080/MK-7902) in combination with pembrolizumab (MK-3745) versus lenvatinib in combination with placebo as first-line therapy for the treatment of advanced hepatocellular carcinoma in adult participants.

The primary hypotheses of this study are that lenvatinib plus pembrolizumab is superior to lenvatinib plus placebo with respect to progression-free survival (PFS) and overall survival (OS).

Clinical Study Identifier: NCT03713593

Find a site near you

Start Over

Railway Hospital of OJSC ( Site 0447)

Saint Petersburg, Russian Federation
  Connect »

City Clinical Oncology Center ( Site 0446)

Saint Petersburg, Russian Federation
  Connect »

Scripps Health ( Site 0644)

La Jolla, CA United States
  Connect »

Advent Health ( Site 0595)

Orlando, FL United States
  Connect »

UCLA ( Site 0589)

Santa Monica, CA United States
  Connect »